BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Huang L, Ge X, Liu Y, Li H, Zhang Z. The Role of Toll-like Receptor Agonists and Their Nanomedicines for Tumor Immunotherapy. Pharmaceutics 2022;14:1228. [PMID: 35745800 DOI: 10.3390/pharmaceutics14061228] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Phoolcharoen W, Shanmugaraj B, Khorattanakulchai N, Sunyakumthorn P, Pichyangkul S, Taepavarapruk P, Praserthsee W, Malaivijitnond S, Manopwisedjaroen S, Thitithanyanont A, Srisutthisamphan K, Jongkaewwattana A, Tomai M, Fox CB, Taychakhoonavudh S. Preclinical evaluation of immunogenicity, efficacy and safety of a recombinant plant-based SARS-CoV-2 RBD vaccine formulated with 3M-052-Alum adjuvant. Vaccine 2023:S0264-410X(23)00312-2. [PMID: 36963999 DOI: 10.1016/j.vaccine.2023.03.027] [Reference Citation Analysis]
2 Catania G, Rodella G, Vanvarenberg K, Préat V, Malfanti A. Combination of hyaluronic acid conjugates with immunogenic cell death inducer and CpG for glioblastoma local chemo-immunotherapy elicits an immune response and induces long-term survival. Biomaterials 2023;294:122006. [PMID: 36701998 DOI: 10.1016/j.biomaterials.2023.122006] [Reference Citation Analysis]
3 Veneziani I, Alicata C, Moretta L, Maggi E. The Latest Approach of Immunotherapy with Endosomal TLR Agonists Improving NK Cell Function: An Overview. Biomedicines 2022;11. [PMID: 36672572 DOI: 10.3390/biomedicines11010064] [Reference Citation Analysis]
4 Shah S, Famta P, Tiwari V, Kotha AK, Kashikar R, Chougule MB, Chung YH, Steinmetz NF, Uddin M, Singh SB, Srivastava S. Instigation of the epoch of nanovaccines in cancer immunotherapy. WIREs Nanomed Nanobiotechnol 2022. [DOI: 10.1002/wnan.1870] [Reference Citation Analysis]